Proposed rule 2026-15671
Modification of Certain Terminology in Title 21; Reopening of the Comment Period
The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the proposed rule that appeared in the Federal Register of May 6, 2026, to modify certain terminology in Title 21 of the Code of Federal Regulations (CFR) to comply with Executive Order (E.O.) 14168, "Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government," issued on January 20, 2025. Specifically, this proposed rule, if finalized, will remove the term "gender" wherever it appears and either replace it with the term "sex," or delete reference to gender, as applicable, along with other editorial changes to improve readability. The Agency is taking this action to allow interested persons additional time to submit comments.
Source-supplied record
Document details
- Document number
- 2026-15671
- Published
- Aug 3, 2026
- Effective
- Not supplied
- Comments close
- May 6, 2026
- Federal Register citation
- 91 FR 48785
Docket identifiers
- Docket No. FDA-2026-N-2886
CFR references
- Title 21, part 10
- Title 21, part 56
- Title 21, part 106
- Title 21, part 201
- Title 21, part 251
- Title 21, part 310
- Title 21, part 312
- Title 21, part 314
- Title 21, part 329
- Title 21, part 600
- Title 21, part 803
- Title 21, part 862
- Title 21, part 866
- Title 21, part 870
- Title 21, part 882
- Title 21, part 1114